DOCSLIB.ORG

KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF NEPHROLOGY KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease VOLUME 2 | ISSUE 4 | AUGUST 2 2012 http://www.kidney-international.org KI_SuppCover_2.4.indd 1 7/11/12 12:00 PM KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease KDIGO gratefully acknowledges the following consortium of sponsors that make our initiatives possible: Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO—The Organization for Transplant Professionals, NKF-Board of Directors, Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern Commercial Services, Vifor Pharma, and Wyeth. Sponsorship Statement: KDIGO is supported by a consortium of sponsors and no funding is accepted for the development of specific guidelines. http://www.kidney-international.org contents & 2012 KDIGO VOL 2 | ISSUE 4 | AUGUST (2) 2012 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease v Tables and Figures vi KDIGO Board Members vii Reference Keys viii Abbreviations and Acronyms 279 Notice 280 Foreword 281 Work Group Membership 282 Abstract 283 Summary of Recommendation Statements 288 Chapter 1: Diagnosis and evaluation of anemia in CKD 292 Chapter 2: Use of iron to treat anemia in CKD 299 Chapter 3: Use of ESAs and other agents to treat anemia in CKD 311 Chapter 4: Red cell transfusion to treat anemia in CKD 317 Methods for Guideline Development 324 Biographic and Disclosure Information 330 Acknowledgments 331 References http://www.kidney-international.org contents & 2012 KDIGO TABLES 289 Table 1. Hb levels in children between 1–19 years for initiation of anemia workup 289 Table 2. Hb levels in children between birth and 24 months for initiation of anemia workup 307 Table 3. Potentially correctable versus non correctable factors involved in the anemia of CKD, in addition to ESA deficiency 308 Table 4. Practical approach in presence of ESA hyporesponsiveness 312 Table 5. Estimated risk associated with blood transfusions per unit transfused 312 Table 6. Estimated risk of transfusion-related infections per unit transfused 314 Table 7. Indications for blood transfusions 318 Table 8. Systematic review topics and screening criteria 318 Table 9. Hierarchy of importance of outcomes 319 Table 10. Literature search yield of primary articles for systematic review topics 319 Table 11. Classification of study quality 320 Table 12. GRADE system for grading quality of evidence 320 Table 13. Final grade for overall quality of evidence 321 Table 14. Balance of benefits and harm 321 Table 15. KDIGO nomenclature and description for grading recommendations 321 Table 16. Determinants of strength of recommendation 322 Table 17. The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines FIGURES 293 Figure 1. Receiver operating characteristic (ROC) curves, examining the utility of iron status tests to distinguish iron deficient from nondeficient study patients 294 Figure 2. Sensitivity and specificity of TSAT and serum ferritin and their combination (TSAT + ferritin) and bone marrow iron (BM iron) to identify correctly a positive erythropoietic response (Z1-g/dl [Z10-g/l] increase in Hb [DHb]) to intravenous iron in 100 nondialysis patients with CKD (areas under the ROCs) 313 Figure 3. Lymphocytotoxic antibody reactivity against random donor test panel in relation to the number of blood transfusions 315 Figure 4. Algorithms for red cell transfusion use in CKD patients Additional information in the form of supplementary materials can be found online at http://www.kdigo.org/clinical_practice_guidelines/anemia.php Kidney International Supplements (2012) 2,v v http://www.kidney-international.org & 2012 KDIGO KDIGO Board Members Garabed Eknoyan, MD Norbert Lameire, MD, PhD Founding KDIGO Co-Chairs Kai-Uwe Eckardt, MD Immediate Past Co-Chair Bertram L Kasiske, MD David C Wheeler, MD, FRCP KDIGO Co-Chair KDIGO Co-Chair Omar I Abboud, MD, FRCP Michel Jadoul, MD Sharon Adler, MD, FASN Simon Jenkins, MBE, FRCGP Rajiv Agarwal, MD Suhnggwon Kim, MD, PhD Sharon P Andreoli, MD Martin K Kuhlmann, MD Gavin J Becker, MD, FRACP Nathan W Levin, MD, FACP Fred Brown, MBA, FACHE Philip K-T Li, MD, FRCP, FACP Daniel C Cattran, MD, FRCPC Zhi-Hong Liu, MD Allan J Collins, MD, FACP Pablo Massari, MD Rosanna Coppo, MD Peter A McCullough, MD, MPH, FACC, FACP Josef Coresh, MD, PhD Rafique Moosa, MD Ricardo Correa-Rotter, MD Miguel C Riella, MD Adrian Covic, MD, PhD Adibul Hasan Rizvi, MBBS, FRCP Jonathan C Craig, MBChB, MM (Clin Epi), DCH, FRACP, PhD Bernardo Rodriquez-Iturbe, MD Angel de Francisco, MD Robert Schrier, MD Paul de Jong, MD, PhD Justin Silver, MD, PhD Ana Figueiredo, RN, MSc, PhD Marcello Tonelli, MD, SM, FRCPC Mohammed Benghanem Gharbi, MD Yusuke Tsukamoto, MD Gordon Guyatt, MD, MSc, BSc, FRCPC Theodor Vogels, MSW David Harris, MD Angela Yee-Moon Wang, MD, PhD, FRCP Lai Seong Hooi, MD Christoph Wanner, MD Enyu Imai, MD, PhD Elena Zakharova, MD, PhD Lesley A Inker, MD, MS, FRCP NKF-KDIGO GUIDELINE DEVELOPMENT STAFF Kerry Willis, PhD, Senior Vice-President for Scientific Activities Michael Cheung, MA, Guideline Development Director Sean Slifer, BA, Guideline Development Manager Kidney International Supplements (2012) 2,vi vi http://www.kidney-international.org & 2012 KDIGO Reference Keys NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE RECOMMENDATIONS Within each recommendation, the strength of recommendation is indicated as Level 1, Level 2,orNot Graded, and the quality of the supporting evidence is shown as A, B, C,orD. Implications Grade* Patients Clinicians Policy Level 1 Most people in your situation would Most patients should receive the recommended The recommendation can be evaluated ‘We recommend’ want the recommended course of action course of action. as a candidate for developing a policy or and only a small proportion would not. a performance measure. Level 2 The majority of people in your situation Different choices will be appropriate for different The recommendation is likely to require ‘We suggest’ would want the recommended course of patients. Each patient needs help to arrive at a substantial debate and involvement of action, management decision consistent with her or his stakeholders before policy can be but many would not. values and preferences. determined. *The additional category ‘Not Graded’ was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence. The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations. Grade Quality of evidence Meaning A High We are confident that the true effect lies close to that of the estimate of the effect. B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. C Low The true effect may be substantially different from the estimate of the effect. D Very Low The estimate of effect is very uncertain, and often will be far from the truth. STAGES OF CHRONIC KIDNEY DISEASE CKD Stage Description GFR (ml/min per 1.73 m2) 1 Kidney damage with normal or increased GFR Z90 2 Kidney damage with mild decreased GFR 60–89 3 Moderate decreased GFR 30–59 4 Severe decreased GFR 15–29 5a Kidney failure o15 (or dialysis) CKD, chronic kidney disease; GFR, glomerular filtration rate. CKD 1–5T notation applies to kidney transplant recipients. a5D if dialysis (HD or PD). CURRENT CHRONIC KIDNEY DISEASE (CKD) NOMENCLATURE USED BY KDIGO CKD Categories Definition CKD CKD of any stage (1–5), with or without a kidney transplant, including both non-dialysis dependent CKD (CKD 1–5ND) and dialysis-dependent CKD (CKD 5D) CKD ND Non-dialysis-dependent CKD of any stage (1–5), with or without a kidney transplant (i.e., CKD excluding CKD 5D) CKD T Non-dialysis-dependent CKD of any stage (1–5) with a kidney transplant Specific CKD Stages CKD 1, 2, 3, 4 Specific stages of CKD, CKD ND, or CKD T CKD 3-4, etc. Range of specific stages (e.g., both CKD 3 and CKD 4) CKD 5D Dialysis-dependent CKD 5 CKD 5HD Hemodialysis-dependent CKD 5 CKD 5PD Peritoneal dialysis-dependent CKD 5 CONVERSION FACTORS OF METRIC UNITS TO SI UNITS Parameter Metric units Conversion factor SI units Ferritin ng/ml 1 mg/l Hemoglobin g/dl 10 g/l Kidney International Supplements (2012) 2, vii vii http://www.kidney-international.org & 2012 KDIGO Abbreviations and Acronyms D Change HEMO Study Kidney Disease Clinical Studies Initiative AGREE Appraisal of Guidelines for Research and Hemodialysis Study Evaluation HLA Human leukocyte antigen BM Bone marrow HR Hazard ratio CBC Complete blood count IM Intramuscular CERA Continuous erythropoietin receptor activator IU International unit CHOIR Correction of Hemoglobin and Outcomes in IV Intravenous Renal Insufficiency KDIGO Kidney Disease: Improving Global Outcomes CI Confidence interval KDOQI Kidney Disease Outcomes Quality Initiative CKD Chronic kidney disease Kt/V Clearance expressed as a fraction of urea or CKiD Chronic Kidney Disease in Children body water volume Prospective Cohort Study MCH Mean
Load more

Recommended publications
  • Specialty Drug List 10-22-12 Final
    Iowa Medicaid Specialty Drug List Effective 10/22/2012 “Specialty” drugs include biological drugs, blood-derived products, complex molecules, and select oral, injectable, and infused medications identified by the Department and reimbursed at AWP-17% plus the dispensing fee. Specialty pricing will be applied to both the brand and generic drug products. NOTE: See the PDL at www.iowamedicaidpdl.com for specific PA criteria for the following drugs. BRAND NAME GENERIC NAME AGENTS FOR GAUCHER DISEASE ELELYSO taliglucerase alfa VPRIV velaglucerase alfa ALS RILUTEK riluzole ALCOHOL DEPENDENCE VIVITROL naltrexone AMINOGLYCOSIDES TOBI tobramycin ANTI-ASTHMATICS ALPHA PROTEINASE INHIBITORS ARALAST proteinase inhibitor ARALAST NP proteinase inhibitor PROLASTIN, C proteinase inhibitor ZEMAIRA alpha-1 proteinase inhibitor ANTIASTHMATIC - BETA - ADRENERGICS BRETHINE INJECTION turbutaline sulfate ANTIASTHMATIC - HYDRO-LYTIC ENZYMES KALYDECO ivacaftor ANTIBIOTICS - MISC. CAYSTON aztreonam lysine for inhal soln ANTI-CATAPLECTIC AGENTS XYREM sodium oxybate oral solution ANTICOAGULANTS ARIXTRA fondaparinux sodium FRAGMIN dalteparin sodium INNOHEP tinzaparin sodium LOVENOX enoxaparin sodium ANTICONVULSANTS SABRIL vigabatrin ANTIDOTES FERRIPROX deferiprone ANTIDOTES - CHELATING AGENTS CHEMET succimer EXJADE deferasirox tab for oral susp Page 1 of 10 ANTIEMETIC - TETRAHYDROCANNABINOL (THC) DERIVATIVES MARINOL dronabinol ANTIFUNGALS - ASSORTED AMBISOME amphotericin B Liposome IV for suspension ANCOBON flucytosine CANCIDAS caspofungin acetate for IV solution
    [Show full text]
  • New Brunswick Drug Plans Formulary
    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
    [Show full text]
  • How Do We Treat Life-Threatening Anemia in a Jehovah's Witness
    HOW DO I...? How do we treat life-threatening anemia in a Jehovah’s Witness patient? Joseph A. Posluszny Jr and Lena M. Napolitano he management of Jehovah’s Witness (JW) The refusal of allogeneic human blood and blood prod- patients with anemia and bleeding presents a ucts by Jehovah’s Witness (JW) patients complicates clinical dilemma as they do not accept alloge- the treatment of life-threatening anemia. For JW neic human blood or blood product transfu- patients, when hemoglobin (Hb) levels decrease Tsions.1,2 With increased understanding of the JW patient beyond traditional transfusion thresholds (<7 g/dL), beliefs and blood product limitations, the medical com- alternative methods to allogeneic blood transfusion can munity can better prepare for optimal treatment of severe be utilized to augment erythropoiesis and restore life-threatening anemia in JW patients. endogenous Hb levels. The use of erythropoietin- Lower hemoglobin (Hb) is associated with increased stimulating agents and intravenous iron has been mortality risk in JW patients. In a study of 300 patients shown to restore red blood cell and Hb levels in JW who refused blood transfusion, for every 1 g/dL decrease patients, although these effects may be significantly in Hb below 8 g/dL, the odds of death increased 2.5-fold delayed. When JW patients have evidence of life- (Fig. 1).3 A more recent single-center update of JW threatening anemia (Hb <5 g/dL), oxygen-carrying patients (n = 293) who declined blood transfusion capacity can be supplemented with the administration reported an overall mortality rate of 8.2%, with a twofold of Hb-based oxygen carriers (HBOCs).
    [Show full text]
  • Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) Policy Number: 2021D0088F Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Intravenous Iron Replacement Therapy (Feraheme®, Definitions ...................................................................................... 3 Injectafer®, & Monoferric®) Applicable Codes .......................................................................... 3 Background.................................................................................... 4 Benefit Considerations .................................................................. 4 Clinical Evidence ........................................................................... 5 U.S. Food and Drug Administration ............................................. 7 Centers for Medicare and Medicaid Services ............................. 8 References ..................................................................................... 8 Policy History/Revision Information ............................................. 9 Instructions for Use ....................................................................... 9 Coverage Rationale See Benefit Considerations This policy refers to the following intravenous iron replacements: Feraheme® (ferumoxytol) Injectafer® (ferric carboxymaltose) Monoferric® (ferric derisomaltose)* The following
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • Venofer ® (Iron Sucrose Injection, USP)
    NDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)- hydroxide in sucrose for intravenous use. Iron sucrose injection has a molecular weight of approximately 34,000 – 60,000 daltons and a proposed structural formula: [Na2Fe5O8(OH) ⋅3(H2O)]n ⋅m(C12H22O11) where: n is the degree of iron polymerization and m is the number of sucrose molecules associated with the iron (III)-hydroxide. Each mL contains 20 mg elemental iron as iron sucrose in water for injection. Venofer® is available in 5 mL single dose vials (100 mg elemental iron per 5 mL) and 10 mL single dose vials (200 mg elemental iron per 10 mL). The drug product contains approximately 30% sucrose w/v (300 mg/mL) and has a pH of 10.5- 11.1. The product contains no preservatives. The osmolarity of the injection is 1,250 mOsmol/L. Therapeutic class: Hematinic CLINICAL PHARMACOLOGY Pharmacodynamics: Following intravenous administration of Venofer®, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. In 22 hemodialysis patients on erythropoietin (recombinant human erythropoietin) therapy treated with iron sucrose containing 100 mg of iron, three times weekly for three weeks, significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment. Pharmacokinetics: In healthy adults treated with intravenous doses of Venofer®, its iron component exhibits first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, non-steady state apparent volume of distribution of 10.0 L and steady state apparent volume of distribution of 7.9 L.
    [Show full text]
  • Specialty Drug Benefit Document
    Louisiana Healthcare Connections Specialty Drug Benefit ouisiana Healthcare Connections provides coverage of a number of specialty drugs. All specialty drugs, such as biopharmaceuticals and injectables, require a prior authorization (PA) to be approved for L payment by Louisiana Healthcare Connections. PA requirements are programmed specific to the drug. Since the list of specialty drugs changes over time due to new drug arrivals and other market conditions, it is important to contact Provider Services at 1-866-595-8133 or check the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com for updates to this benefit. Requests for specialty drugs can be submitted to Louisiana Healthcare Connections by filling out the Medication Prior Authorization Form that is available on the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com and faxing the request as instructed on the form. Louisiana Healthcare Connections members can receive the specialty drugs they require at any outpatient pharmacy enrolled in our pharmacy network that can supply specialty drugs. Providers that wish to have drugs distributed by a SPECIALTY PHARMACY should FAX the request to 1-866-399-0929 for review. If a provider wishes to dispense a specialty drug from OFFICE STOCK, the provider should FAX the request to Louisiana Healthcare Connections at 1-877-401-8172 for review. BRAND NAME INGREDIENTS SPECIAL INSTRUCTIONS ACTEMRA TOCILIZUMAB ACTHAR HP CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA-1B ADAGEN PEGADEMASE BOVINE Limited Distribution
    [Show full text]
  • Management of Anemia in Non-Dialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives
    Kidney360 Publish Ahead of Print, published on July 1, 2020 as doi:10.34067/KID.0001442020 Management of Anemia in Non-Dialysis Chronic Kidney Disease: Current recommendations, real-world practice, and patient perspectives Murilo Guedes1,2, Bruce M. Robinson1,3, Gregorio Obrador4, Allison Tong5,6, Ronald L. Pisoni1, Roberto Pecoits-Filho1,2 1Arbor Research Collaborative for Health, Ann Arbor, MI, USA 2School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil 3University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA 4Universidad Panamericana - Campus México, DF, MX, Mexico 5 Sydney School of Public Health, University of Sydney, Sydney, Australia 6 Centre for Kidney Research, The Children’s Hospital at Westmead, Sydney, Australia Corresponding Author Roberto Pecoits-Filho Arbor Research Collaborative for Health 3700 Earhart Road Ann Arbor, MI 48105 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abstract In non-dialysis chronic kidney disease (ND-CKD), anemia is a multi-factorial and complex condition in which several dysfunctions dynamically contribute to a reduction in circulating hemoglobin (Hb) levels in red blood cells. Anemia is common in CKD, and represents an important and modifiable risk factor for poor clinical outcomes. Importantly, symptoms related to anemia, including reduced physical functioning and fatigue, have been identified as high priorities by patients with CKD. The current management of anemia in ND-CKD, i.e., parameters to initiate treatment, Hb and iron indexes targets, choice of therapies, and impact of treatment on clinical and patient-reported outcomes, remains controversial. In this review article, we explore the epidemiology of anemia in NDD-CKD, and revise current recommendations and controversies in its management.
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • OMONTYS® Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use Dosage Form Strengths OMONTYS® safely and effectively. See full prescribing information for OMONTYS. Single use vials 2 mg/0.5 mL, 3 mg/0.5 mL, (preservative-free) 4 mg/0.5 mL, 5 mg/0.5 mL, and OMONTYS® (peginesatide) Injection, 6 mg/0.5 mL for intravenous or subcutaneous use Single use pre-filled syringes 1 mg/0.5 mL, 2 mg/0.5 mL, Initial U.S. Approval: 2012 (preservative-free) 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, and 6 mg/0.5 mL WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL Multiple use vials 10 mg/mL and 20 mg/2 mL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, (with preservative) THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE -------------------------------CONTRAINDICATIONS------------------------------ See full prescribing information for complete boxed warning. Uncontrolled hypertension (4). Chronic Kidney Disease: In controlled trials, patients experienced greater risks for -----------------------WARNINGS AND PRECAUTIONS------------------------ death, serious adverse cardiovascular reactions, and stroke Increased Mortality, Myocardial Infarction, Stroke, and when administered erythropoiesis-stimulating agents (ESAs) Thromboembolism: Using ESAs to target a hemoglobin level of to target a hemoglobin level of greater than 11 g/dL (5.1). greater than 11 g/dL increases the risk of serious adverse No trial has identified a hemoglobin target level, ESA dose, or cardiovascular reactions and has not been shown to provide dosing strategy that does not increase these risks (5.1). additional benefits (5.1).
    [Show full text]
  • Ferric Maltol 30Mg Hard Capsules (Feraccru®) SMC No
    ferric maltol 30mg hard capsules (Feraccru®) SMC No. (1202/16) Shield TX UK Limited 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows: ADVICE: following a full submission ferric maltol (Feraccru®) is not recommended for use within NHS Scotland. Indication under review: in adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). In a pooled analysis of two phase III studies in IBD patients with IDA who had failed previous treatment with oral ferrous products, there was a significantly greater increase in haemoglobin concentrations after 12 weeks of ferric maltol treatment compared with placebo. The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium Published 12 December 2016 1 Indication In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). Dosing Information One capsule twice daily, morning and evening, on an empty stomach. Treatment duration will depend on severity of iron deficiency but generally at least 12 weeks treatment is required. The treatment should be continued as long as necessary to replenish the body iron stores according to blood tests. Ferric maltol capsules should be taken whole on an empty stomach (with half a glass of water) as the absorption of iron is reduced when it is taken with food.
    [Show full text]
  • Supplemental Guide: Nephrology
    Supplemental Guide for Nephrology Supplemental Guide: Nephrology March 2020 1 Supplemental Guide for Nephrology TABLE OF CONTENTS INTRODUCTION ............................................................................................................................. 3 PATIENT CARE .............................................................................................................................. 4 Acute Kidney Injury ...................................................................................................................... 4 Chronic Dialysis Therapy ............................................................................................................. 6 Chronic Kidney Disease ............................................................................................................... 8 Transplant .................................................................................................................................. 10 Fluid and Electrolytes ................................................................................................................. 12 Hypertension .............................................................................................................................. 13 Competence in Procedures ........................................................................................................ 15 MEDICAL KNOWLEDGE .............................................................................................................. 17 Physiology and Pathophysiology ..............................................................................................
    [Show full text]